These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27777386)

  • 41. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences between pharmacokinetics and toxicokinetics.
    Welling PG
    Toxicol Pathol; 1995; 23(2):143-7. PubMed ID: 7569668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Interactions between nutrition and drugs].
    Czok G
    Z Ernahrungswiss; 1976 Jun; 15(2):188-200. PubMed ID: 969708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.
    Parrott N; Paquereau N; Coassolo P; Lavé T
    J Pharm Sci; 2005 Oct; 94(10):2327-43. PubMed ID: 16136543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experimental models for predicting drug absorption and metabolism.
    Alqahtani S; Mohamed LA; Kaddoumi A
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1241-54. PubMed ID: 23687990
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absorption, metabolism, and other factors that influence drug exposure in toxicology studies.
    Mayer PR
    Toxicol Pathol; 1995; 23(2):165-9. PubMed ID: 7569671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ontogeny of oral drug absorption processes in children.
    Mooij MG; de Koning BA; Huijsman ML; de Wildt SN
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1293-303. PubMed ID: 22686526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
    Zhang T; Heimbach T; Lin W; Zhang J; He H
    J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.
    Landskroner KA; Hess P; Treiber A
    Xenobiotica; 2011 Aug; 41(8):687-700. PubMed ID: 21486193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pharmacokinetics.
    Atkinson AJ; Kushner W
    Annu Rev Pharmacol Toxicol; 1979; 19():105-27. PubMed ID: 378099
    [No Abstract]   [Full Text] [Related]  

  • 55. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review of drug bioavailability following gastrointestinal surgery.
    Santamaría MM; Villafranca JJA; Abilés J; López AF; Rodas LV; Goitia BT; Navarro PU
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1531-1545. PubMed ID: 30136101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Age-related changes in pharmacokinetics and pharmacodynamics].
    Akishita M
    Nihon Rinsho; 2013 Nov; 71(11):1888-91. PubMed ID: 24397155
    [No Abstract]   [Full Text] [Related]  

  • 59. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond.
    Artursson P; Borchardt RT
    Pharm Res; 1997 Dec; 14(12):1655-8. PubMed ID: 9453050
    [No Abstract]   [Full Text] [Related]  

  • 60. [Recent advance in predicting oral bioavailability].
    Ma GL; Cheng YY
    Yao Xue Xue Bao; 2006 Oct; 41(10):917-20. PubMed ID: 17184106
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.